The Arguments WHAT THE INDUSTRY ARGUES Supporters of PBMs argue they serve as intermediaries between insurers, pharmacies, and drug manufacturers, negotiating discounts and managing formularies to reduce prescription drug costs for health plans and consumers. They contend that PBMs leverage their large purchasing power to secure rebates from drug manufacturers, which can lower overall spending…
The Arguments WHAT THE INDUSTRY ARGUES Supporters of Medicare Advantage argue that these privately administered plans often bundle hospital, medical, and sometimes prescription drug and dental coverage into a single plan, potentially offering lower out-of-pocket costs and additional benefits not available under traditional Medicare. They contend that the managed-care model can coordinate care more efficiently…
The Arguments WHAT THE INDUSTRY ARGUES Supporters of Medicare highlight that it provides essential healthcare coverage for Americans 65 and older, including hospital stays (Part A), doctor visits and outpatient services (Part B), and prescription drugs (Part D). Medicare Advantage plans (Part C) may bundle additional benefits. Proponents argue Medicare forms a critical safety net…
The Arguments WHAT THE INDUSTRY ARGUES Insurers and plan administrators argue that prior authorization serves as a necessary cost-control and quality-assurance tool. By requiring advance approval before covering certain drugs, procedures, or services, insurers say they can verify that a treatment is medically appropriate, prevent unnecessary or duplicative care, and steer patients toward evidence-based options….
The Arguments WHAT THE INDUSTRY ARGUES Supporters point to evidence that the No Surprises Act is working as intended. According to a report cited by Techtarget, there has been greater in-network participation since the law took effect, suggesting that providers are increasingly joining insurance networks rather than remaining out-of-network. Proponents argue this directly reduces the…
The Arguments WHAT THE INDUSTRY ARGUES Supporters of the price transparency mandate argue that the rules are producing real results. A study cited by Techtarget.com links hospital price transparency to lower cancer care costs, suggesting that publishing pricing data can drive down expenses. Proponents also note that health systems and insurers are actively using the…
The Arguments WHAT THE INDUSTRY ARGUES Proponents of chargemasters argue that hospitals need a comprehensive list of standard charges for every service, supply, and procedure to maintain consistent internal accounting and billing infrastructure. They contend the chargemaster serves as a necessary starting point for negotiations with insurers and helps hospitals ensure they capture all billable…
The Arguments WHAT THE INDUSTRY ARGUES Proponents argue that Certificate of Need laws, which require healthcare providers to obtain state approval before building new facilities, expanding capacity, or acquiring major equipment, help prevent unnecessary duplication of services, control healthcare costs, and ensure that underserved and rural communities maintain access to care by preventing market oversaturation…
The Arguments WHAT THE INDUSTRY ARGUES Some argue that higher US drug prices reflect the cost of pharmaceutical innovation and research, and that government price negotiations or reference pricing could reduce costs for American consumers. The Trump administration claimed it was securing deals with pharmaceutical companies to bring prices down, asserting Americans would pay ‘the…
The Arguments WHAT THE INDUSTRY ARGUES Supporters of the current pricing system argue that price variation reflects genuine differences in hospital quality, staffing levels, geographic cost of living, facility overhead, and the complexity of individual patient cases. Hospitals that invest more in specialized equipment, experienced surgical teams, and comprehensive post-operative care may justifiably charge higher…